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Visceral pain is the most common reason for physician visits in US. Glutamate is the major excitatory neurotransmitter and
mediates visceral nociceptive neuro-transmission and hypersensitivity. Removal of extracellular glutamate is predominantly
mediated by glial glutamate transporter-1 (GLT-1). The pharmacological approach to up-regulate GLT-1 by 1 week administration
of ceftriaxone (CTX) has been successful to mitigate visceral nociception. The present study shows that intrathecal delivery
of selective GLT-1 antagonist dihydrokainate reversed CTX-blunted visceral nociceptive response, suggesting a spinal site of
action. The role of GLT-1 up-regulation in animal models of colitis was studied. CTX treatment reversed TNBS-induced visceral
hypersensitivity. In addition, CTX treatment initiated one week after the onset of DSS-induced visceral inﬂammation also
attenuated visceral hypersensitivity, revealing a potential therapeutic eﬀect. Cephalothin, a cephalosporin antibiotic lacking GLT-
1 induction activity, failed to attenuate visceral nociception. CTX-induced changes in fecal microbiota do not support a role of
probiotic eﬀects in mitigating visceral nociception/hypersensitivity. Finally, adeno-associated virus serotype 9-mediated GLT-1
over-expression was eﬀective to mitigate visceromotor response to 60mmHg colo-rectal distension. These studies indicate that
GLT-1 over-expression is a novel and eﬀective method to attenuate visceral nociception, and is deserving of further study as a
translationally relevant approach to treat visceral pain.
1.Introduction
Visceral pain, deﬁned as pain associated with the internal
organs, is a major clinical problem aﬀecting up to 25% of
the general US population and is the most common reason
for physician visits in the USA. Lower pain thresholds to
aversive stimuli are common, due to visceral organ primary
aﬀerentsensitization,hyperexcitabilityofsecond-orderpain-
transmitting neurons, or dysregulation of descending mod-
ulation of nociception [1]. These pain categories are the
most refractory to eﬀective treatment, in part due to its di-
verse nature and the contribution of distinct and redundant
mechanisms that are incompletely understood and diﬀer
from the better studied somatic nociceptive system [2]. In-
ﬂammation plays a signiﬁcant role in the peripheral and
central sensitization seen in a subgroup of subjects [3].
A series of exciting recent ﬁndings in the subclinical
study of visceral pain shows that a novel strategy to de-
crease synaptic glutamate by upregulating the physiologi-
cally dominant glutamate transporter GLT-1 is eﬀective to
mitigate visceral nociception [4–6]. Evidence suggests that
the expression of new protein is stimulated by the β-lac-
tam antibiotic ceftriaxone (CTX) [7, 8]. Regarding clinical
potentialofthisapproach,pharmacologicGLT-1overexpres-
sion utilizing the cephalosporin antibiotic ceftriaxone has
reached Phase III clinical trials for the treatment of amy-
otrophic lateral sclerosis [9], http://clinicaltrials.gov/ct2/
show/NCT00349622?term=Ceftriaxone&amp;rank=4,andis
being explored for other CNS disorders [10]. In this study
of antinociceptive eﬃcacy, experiments are designed to de-
termine (1) the site of action of CTX-mediated GLT-1 upreg-
ulation, (2) whether viral transfection of GLT-1 utilizing2 Pain Research and Treatment
translationally superior adenoassociated virus serotype 9
(AAV9) mitigates visceral nociception, (3) the eﬀectiveness
of GLT-1 upregulation to mitigate inﬂammogen-mediated
visceral hyperalgesia, and (4) the relative role of enhanced
glutamate transporter activity, anti-inﬂammatory action,
and changes in intestinal microbiota to mitigate visceral no-
ciception. The results (i) conﬁrm a spinal site of action
of CTX-induced enhanced glutamate transporter activity
to mitigate visceral nociception due to colonic distension,
(ii) reveal eﬀectiveness of AAV9-mediated transfection of
GLT-1 to blunt visceral nociception and (iii) demonstrate
eﬀectiveness of both preemptive and therapeutic GLT-1
overexpression to mitigate inﬂammogen-mediated visceral
hyperalgesia while not aﬀecting murine locomotor activity.
2. Methods
2.1. Animals. Two-to-three-month old FVB/N mice of both
genders were used for the behavioral studies. CR57/BL mice
wereusedfortheadenoassociatedvirus(AAV9)studies.Mice
were maintained on a twelve-hour day–twelve-hour night
cycle and were housed in groups of ﬁve with water and food.
Allprotocols were approved by the Institutional Animal Care
andUseCommitteeintheOhioStateUniversityandadhered
to the guidelines of the Committee for Research and Ethical
Issues of the International Association for the Study of Pain.
2.2. Drug Administration. Ceftriaxone (CTX; Sigma, St.
Louis, Mo, USA) was prepared in saline and was admin-
istrated intraperitoneally 200mg (302μmoles)/Kg/day in a
10ml/kg volume for one week. Cephalothin (CLT) was ad-
ministered in an equimolar dose, and in the same route and
duration as CTX. Normal saline was used as control injec-
tions for these experiments.
2.3.AAV9-GLT-1Transfection. ThehumanGLT-1cDNAwas
subcloned from a construct obtained as a gift from Dr.
Jeﬀrey Rothstein (Johns Hopkins University). The Kaspar
Laboratory routinely achieves >1013 viral particles from
AAV preparations [11]. For neonate injections in 19–26-d-
old pups, a light microscope was used to visualize the tail
vein. Vector solution was drawn into a 3/10cc 30-gauge
insulin syringe. The needle was inserted into the vein, and
the plunger was manually depressed. Virus injections were in
a total volume of 100ml of PBS supplemented with 0.001%
pluronic F68. A total of 4 × 1011 DNase-resistant particles
of scAAV9-CB-GLT-1 were injected. A correct injection
was veriﬁed by noting blanching of the vein. After the
injection,pupswerereturnedtotheircage.Experimentswere
performed in 8-week-old adult mice.
2.4. Colorectal Distention. Among the pseudoaﬀective re-
sponsescommonlyemployedinrodentsasanindexfornoci-
ception is the visceromotor response to colorectal distension
(CRD). CRD was performed as described previously [12].
Brieﬂy, animals were surgically implanted with two electro-
myography(EMG)electrodesfashionedfrominsulatedsilver
wire in the external oblique muscle. Three days after recov-
ery from surgery, the visceromotor response to colorectal
distention was elicited by intracolonic balloon distention in
triplicate at 15, 30, 45, and 60mmHg pressure. The data was
analyzed as the number of electromyographic spikes above
baseline using Spike2 software (CED, UK).
2.5. Intrathecal Administration. In some experiments, one
hour before colorectal distention, animals were lightly anes-
thetizedbyisoﬂurane.Thehairinthemidlineofthebackwas
shaven, and the locus of the cauda equina was determined
as described previously [13]. A 30-gauge needle connected
to a 10μl Hamilton syringe was inserted through the L5-L6
vertebra to reach the dura at the lumbosacral spinal level.
A characteristic tail ﬂick occurred after correct placement
of the needle. 5μl of vehicle or dihydrokainate (DHK) at
diﬀerent concentrations (3, 0.3, 0.003mM) was delivered
into the intrathecal space over one minute, and the animals
were prepared for colorectal distension.
2.6. Intracisternal Administration. In some experiments, one
hour before colorectal distention, animals were lightly anes-
thetized by isoﬂurane. Hair was shaven on the dorsal aspect
of the neck and was removed, and a 0.5cm diameter steel bar
was put underneath the neck. A 30-gauge needle connected
to a 50μl Hamilton syringe was carefully advanced to pene-
trate the allantoin-occipital membrane to access the cisterna
magna. Vehicle, 0.3 or 3.0mM dihydrokainate (DHK), was
then delivered in a 5μl volume into the cistern magna, and
the animals were prepared for colorectal distension.
2.7. Colonic Inﬂammation with Trinitrobenzene Sulfonic Acid
(TNBS). Two groups of animals were treated with intra-
colonic TNBS (7mg/ml) and another two cohorts treated
with intracolonic vehicle prepared in 50% ethanol and deliv-
ered through a syringe attached to a lubricated polyethylene
catheter (PE20) two centimeters proximal to the anus in
a 100μl volume. After instillation (day 0), mice were held
head-down by lifting up the tail for 1 min to ensure exposure
of distal colon to injectate. CTX 200mg/Kg/day or vehicle
injections were administered intraperitoneally at 10:00 am
days 0–6. Mice were utilized on day 7 for behavioral tests,
myeloperoxidase (MPO) assay, and immunoblot analysis.
2.8. Colonic Inﬂammation with DSS. Two groups of animals
were administered ﬁve mililliters daily of normal drinking
water and another two groups administered 4% dextran
sodium sulfate (DSS) dissolved in the drinking water daily
for 1 week (days 0 to 6). Mice receiving 4% DSS typically
develop colitis by day 7 [14]. All animals were then switched
to normal drinking water for the remainder of the study.
Ceftriaxone (200mg/Kg/day; ip) was then administered
therapeutically for one week (days 7–13) in one cohort
treated with 4% DSS and one cohort treated with normal
drinking water. Similarly, vehicle was injected on days 7–13
in one cohort treated with 4% DSS and one cohort treated
with normal drinking water. Mice were utilized on day 14 for
behavioral and biochemical analysis.Pain Research and Treatment 3
2.9. Myeloperoxidase (MPO) Assay. As a measure of colonic
inﬂammation, 1cm of the distal colon was dissected from
animals and samples were minced and homogenized 30
strokes by a motor-driven grinder in 1ml ice-cold 50mM
potassium phosphate buﬀe r( p H6 . 0 )w i t h0 . 5 %h e x a d e -
cyltrimethylammonium bromide (Sigma). Samples subse-
quently underwent 30s sonication and three freeze-thaw
cycles in liquid nitrogen. After brief sonication, samples were
centrifuged at 10,000rpm for 10min at 4◦C. Supernatant
was collected to measure MPO activity. 200μlo f5 0 m M
potassium phosphate (pH 6.0) containing 0.167mg/ml O-
dianisidine dihydrochloride (Sigma) and 0.0005% hydrogen
peroxidewasloadedasreactionbuﬀerina96-wellplate.20μl
of supernatant sample was then mixed with reaction buﬀer.
Two minutes later, absorbance was read at 460nm by a spec-
trometer (PowerWave XS, BioTek). Protein concentration
was accessed by adding the 1μl sample into 200μl coomassie
bluebuﬀer(Pierce)inthesame96-wellplate,andabsorbance
was read at 595nm. The unit of MPO was deﬁned by the
change in 460nm absorbance per mg of protein sample in
two minutes.
2.10. Immunoblotting. Brieﬂy, 20μg of protein sample dis-
sected from mice lumbosacral spinal cord was sonicated,
loaded in 8% SDS-PAGE gel, and transferred to nitrocel-
lular membranes. After one-hour blocking, the membranes
underwent over-night primary antibody (rabbit anti-GLT-1
antibody, 1:1000; rabbit anti-actin antibody, 1:1000, Santa
Cruz) and one-hour secondary antibody (HRP-conjugated
rabbit IgG, 1:3000, Santa Cruz) incubation, followed by X-
ﬁlm exposure with Enhanced Chemiluminescent Substrate
(Pierce).
2.11. Rotarod Test. Mice were trained on an accelerating
rotarod (Columbus Instrument, Columbus, OH) 3 times per
day for 3 days. The cylinder of the rotarod was 71cm long,
and its diameter was 3.2cm. Mice were allowed to explore
the rotarod for 2min without rotation. The velocity of the
rod was set to increase from 0 to 40rpm in 5min. Mice with
stable 300s performance on the 3rd day were used later. At
the end of baseline testing, animals were divided into two
groups and one group treated with CTX 200mg/Kg/day and
the other cohort administered vehicle i.p. After this one-
week treatment, mice were tested three times per day for
3 days with 1-hour interval, following the same protocol.
The latency to fall oﬀ the apparatus in the three trials
was recorded, and the 3-day data from individual mouse
was averaged. Signiﬁcant diﬀerence was assessed by using
Student’s t-test.
2.12. Statistics. Multiple group diﬀerences were analyzed by
ANOVA followed by post-hoc LSD analysis.
3. Results
3.1. Intrathecal (it) DHK Treatment Dose-Dependently Re-
versed Attenuated Visceral Nociceptive Response Produced
by GLT-1 Overexpression. GLT-1 overexpression induced
by 1-week CTX treatment produced a signiﬁcant 41–60%
reduction in the visceromotor response to 45 and 60mmHg
colorectal distention (1-week CTX + it vehicle), compared
to animals treated with 1-week vehicle + it vehicle (Figures
1(a)–1(c)). To assess whether spinal GLT-1 overexpres-
sion mediates attenuation of the visceromotor response to
colorectal distension, the selective GLT-1 antagonist dihy-
drokainic acid (DHK; 5μl, 3mM) was injected into the
intrathecal space (it) one hour before the graded visceromo-
tor response to colorectal distension was elicited. In ani-
mals with GLT-1 overexpression produced by 1-week CTX,
intrathecal DHK (1-week CTX + it DHK 3mM) reversed
the blunted visceromotor response produced by GLT-1
overexpression (1-week CTX + it vehicle; Figure 1(a)).
Notably, the 1-week vehicle + it DHK 3mM group (Fig-
ure 1(a)) produced an augmented visceromotor response to
45 and 60mmHg colorectal distension compared to controls
(1-week vehicle + it vehicle), likely due to enhanced extracel-
lularglutamate[15].Tofurtherinvestigatethedose-response
relationship of intrathecal DHK to reverse blunted viscero-
motor response caused by GLT-1 overexpression, a tenfold
lower dose of DHK (0.3mM) was injected one hour prior to
colorectaldistention(Figure 1(b)).Thegrouptreatedwith1-
week vehicle + the lower dose (0.3mM) of it DHK was still
able to reverse the blunted visceromotor response to 45 and
60mmHg colorectal distension seen in the 1-week CTX + it
vehicle group (Figure 1(b)), even though the 0.3mM dose
of it DHK did not produce enhanced visceromotor response
to 45 and 60mmHg colorectal distension compared to the
1-week vehicle + it vehicle cohort (Figure 1(b)). Moreover,
the DHK-mediated reversal of the inhibitory eﬀect of 1-week
CTX was lost after a further 100-fold decrease in the dose
of DHK (1-week CTX + it DHK 0.003mM) (Figure 1(c)).
Thus, the data suggests a DHK-mediated dose-dependent
reversal of the blunted visceromotor response to colorectal
distension caused by GLT-1 overexpression.
3.2. Intracisternal (ic) DHK Pretreatment Did Not Reverse
Attenuated Visceral Nociceptive Response Caused by GLT-
1 Overexpression. Given the putative role of hindbrain
glutamate receptors to modulate pain transmission [16], the
role of enhanced activity of supraspinal GLT-1 in mediating
inhibition of the visceromotor response was investigated.
DHK was delivered into the cisterna magna one hour prior
to colorectal distension (Figures 2(a) and 2(b))a td o s e s
3.0 and 0.3mM previously shown eﬀective to reverse the
inhibitory eﬀect of GLT-1 overexpression after intrathecal
administration (Figures 1(a) and 1(b)). Neither dose of
intracisternal DHK reversed the attenuated visceromotor
response in 1 week CTX + it vehicle-treated animals (Figures
2(a) and 2(b)). These data suggests that GLT-1 overexpres-
sion in the hindbrain does not mediate the attenuation of
the visceromotor response to colorectal distension.
3.3. GLT-1 Overexpression Reversed TNBS-Induced Visceral
Hyperalgesia. Colonic inﬂammation causes visceral hyperal-
gesia [17] and this association is clinically relevant. To test
the eﬀectiveness of GLT-1 overexpression on inﬂammogen-
mediated visceral hyperalgesia, the inﬂammogen TNBS4 Pain Research and Treatment
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Figure 1: Comparison of visceromotor responses (VMR spikes) to colorectal distension (CRD) between (i) animals treated 1 week with
vehicle (intraperitoneal; ip) and vehicle (intrathecal; it) given 1 hour before CRD, (ii) animals treated 1 week with vehicle (ip) and
dihydrokainate (DHK 3mM, it; n = 4 (a), DHK 0.3mM, it; n = 8 (b), and DHK 0.003mM, it; n = 7( c ) )g i v e n1h o u rb e f o r eC R D ,
(iii) animals treated 1 week with ceftriaxone (CTX 200mg/kg, ip) and vehicle (it) given 1 hour before CRD, and (iv) animals treated 1 week
with (CTX 200mg/kg, ip) and (DHK 3mM, it; n = 6 (a), DHK 0.3mM, it; n = 8( b ) ,a n dD H K0 . 0 0 3m M ,i t ;n = 7( c ) )g i v e n1h o u r
before CRD. Data from the 1-week vehicle + it vehicle group and 1-week CTX + it vehicle group are from the same animals in (a)–(c).
∗P< 0.05 compared to the 1-week Veh + it Veh group. Intrathecal DHK reversed the attenuated visceromotor response caused by 1-week
CTX treatment at 3 and 0.3mM but not 0.003mM doses.
Table 1: Colonic myeloperoxidase (MPO) tissue levels 1 week aft-
er intracolonic (i-colo) TNBS; eﬀect of concomitant ceftriaxone
(CTX).
Treatment (n) Mean ± SEM (units/mg)
1wk veh + i-colo veh [22]0 .23 ±0.05
1wk CTX + i-colo veh [22]0 .18 ±0.03
1wk veh + i-colo TNBS [13]0 .51 ±0.04a
1wk CTX + i-colo TNBS [13]0 .23 ±0.04b
One-week CTX treatment (200mg/Kg/day (302μmole), ip) attenuated
colonic inﬂammation caused by intracolonic (i-colo) TNBS instillation, as
measuredbyMPOactivity. aP<0.005comparedto1-weekveh+i-coloveh;
bP<0.005 compared to 1-week veh + i-colo TNBS).
(0.1ml; 7mg/ml) was instilled into the distal colon 1 week
before the visceromotor response to colorectal distension
was elicited. TNBS was administered at day 0, and CTX
(200mg/Kg, ip) was administrated at 10:00am daily from
days 0 through 6. Mice were exposed to colorectal distension
and/or tissues harvested at day 7. Intracolonic TNBS resulted
in a signiﬁcant increase (42–69%) in the visceromotor re-
sponse to 30, 45 and 60mmHg colorectal distension, com-
paredtocontrolanimals(Figure 3).GLT-1overexpressionby
1-week CTX treatment reversed colitis-enhanced visceromo-
tor response to the 30, 45 and 60mmHg CRD, compared to
TNBS-treated animals (Figure 3).
Glutamate receptor activation mediates colonic inﬂam-
mation [17, 18]a sw e l la sC N Se v e n t st h a tm e d i a t eh y p e r -
algesia [16]. Thus, the relative role of the anti-inﬂammatory
eﬀects of decreased glutamatergic tone by GLT-1 overexpres-
sion was explored. Myeloperoxidase (MPO) activity as an
index of inﬂammation [19] was measured in distal colon
samples 7 days after intracolonic TNBS treatment to assess
eﬀectsofconcomitant1-weekCTXoncolonicinﬂammation.
Intracolonic TNBS treatment led to a signiﬁcant increase in
MPO activity, compared to vehicle-treated animals (Table 1;
P<0.005). 1-week CTX treatment inhibited the enhanced
MPO activity produced by colonic TNBS administration
(Table 1; P<0.005). These data suggest that pharma-
cologic GLT-1 overexpression was able to attenuate bothPain Research and Treatment 5
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Figure 2: Comparison of visceromotor responses (VMR spikes)
to colorectal distension (CRD) between (i) animals treated 1 week
with vehicle (intraperitoneal; ip) and vehicle (intracisternal; ic)
given 1 hour before CRD; n = 7, (ii) animals treated 1 week with
vehicle (ip) and dihydrokainate (DHK 0.3mM, ic; n = 6 (a) and
DHK 3mM, ic; n = 6 (b), given 1 hour before CRD; n = 7, (iii)
animals treated 1 week with ceftriaxone (CTX 200mg/kg, ip) and
vehicle (ic) given 1 hour before CRD, and (iv) animals treated 1
weekwith(CTX200mg/kg,ip)and(DHK0.3mM,ic;n = 6(a)and
DHK 3mM, ic; n = 4 (b), given 1 hour before CRD. Data from the
1-week vehicle/ic vehicle group and 1-week CTX/ic vehicle group
are from the same animals in (a) and (b). ∗P<0.05 compared to
the 1-week Veh + ic Veh group. Intracisternal DHK was ineﬀective
to reverse the attenuated visceromotor response caused by 1-week
CTX treatment.
the intracolonic TNBS-elevated visceromotor response to
colorectal distension (Figure 3), as well as the induced in-
ﬂammatory response.
3.4. Eﬀect of a Cephalosporin Antibiotic Cephalothin (CLT)
Not Enhancing GLT-1 Expression on Visceral Hyperalgesia
I n d u c e db yT N B S .To further explore the putative role of
the anti-inﬂammatory eﬀect of cephalosporin antibiotics to
mediate antinociception, cephalothin (CLT), a cephalospo-
rin antibiotic not eﬀective to enhance GLT-1 expression
(Figure 4) was utilized to investigate its eﬀect on the
enhanced visceromotor response induced by intracolonic
TNBS. Immunoblots show that, in contrast to 1-week
CTX, administration of equimolar 1-week CLT ((302μmole)
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Figure 3:Theeﬀect ofGLT-1overexpression ontheintracolonic (i-
colo) TNBS-sensitized visceromotor response to graded colorectal
distension were compared in female mice. In animals treated
with 1-week vehicle and then intracolonic TNBS (100μl, 7mg/ml)
(•), administered 1 week before the study, signiﬁcant increased
visceromotor response to colorectal distension (∗P<0.05) was
observed,comparedto1-weekvehicleandintracolonicvehicle( ).
One-week CTX treatment abolishes the enhanced visceromotor
response to colorectal distension caused by intracolonic TNBS
(). n = 7-8/group. ∗P<0.01 compared to 1-week vehicle +
intracolonic vehicle group.
Table 2: Colonic myeloperoxidase (MPO) issue levels 1 week after
intracolonic TNBS; eﬀect of concomitant cephalothin (CLT).
Treatment (n) Mean ± SEM (units/mg)
1wk veh + i-colo veh [23]0 .24 ±0.03
1wk CLT + i-colo veh [23]0 .23 ±0.03
1wk veh + i-colo TNBS [23]0 .56 ±0.09a
1wk CLT + i-colo TNBS [23]0 .29 ±0.04b
One-week cephalothin treatment ((302 μmole) 126mg/Kg/day, ip) was
eﬀectivetoattenuatecolonicinﬂammationcausedbyintracolonic(ic)TNBS
instillation, as measured by MPO activity. aP<0.005 compared to 1-week
veh + ic veh; bP<0.005 compared to 1-week veh + ic TNBS).
126mg/Kg/day) did not increase the GLT-1 protein level in
the spinal cord, compared to vehicle-treated mice (Figure 4).
In contrast to 1-week CTX, 1-week CLT treatment did not
signiﬁcantly attenuate intracolonic TNBS-induced hyperal-
gesia(Figure 5),butsigniﬁcantlyreducedtheenhancedMPO
response caused by intracolonic TNBS (Table 2), These data
taken together suggest that the anti-inﬂammatory property
of cephalosporins alone do not inhibit the hyperalgesia
produced by inﬂammogen TNBS and implicates the GLT-1
overexpression property of 1-week CTX as a mediator of the
antinociceptive eﬀect.
3.5. Therapeutic GLT-1 Overexpression Reversed Ongoing Vis-
ceral Hypersensitivity Induced by DSS. A key question related6 Pain Research and Treatment
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Figure 4: CLT treatment did not alter spinal GLT-1 expression.
(a) Representative western blot of GLT-1 protein levels in the
spinal cords of CLT- and vehicle-treated mice. (b) Intensity
analysis of western bands showed that one-week CLT treatment
(200mg/Kg/day) did not alter GLT-1 protein expression compared
to controls (n = 3, each group; P>0.05).
to potential therapeutic utility of antinociceptive strategies
to overexpress GLT-1 is its eﬀectiveness after the initiation
of algesia. This study utilized the DSS-induced colitis model,
where 5ml of 4% DSS in the drinking water was provided
daily to two groups of mice for one week. Comparison
cohorts of two groups of mice were administered normal
drinking water for week one. All animals were returned to
normal drinking water for week 2, and GLT-1 overexpression
waspr oducedby1-weekCTX(200mg/Kg,ipdaily)fr omda y
7throughday13intwogroupsofmice(1-weekoralDSSand
normaldrinkingwatercontrol),andtwogroups(1-weekoral
DSSandnormal drinking watercontrol)weretreatedwith ip
vehicle daily for 1 week. In response to colorectal distension
performed at day 14, DSS treated animals displayed a
signiﬁcantly increased (36–60%) visceromotor response to
45 and 60mmHg colorectal distension, compared to control
animals (Figure 6). At day 14, DSS-treated animals also
exhibited severe colitis in the distal colon, as measured by
a signiﬁcant increase in MPO activity compared to control
animals (Table 3). Therapeutic CTX treatment signiﬁcantly
reversed the DSS-enhanced visceromotor response to the
45 and 60mmHg CRD tests, compared to DSS-treated
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Figure 5: The eﬀect of 1-week cephalothin (CLT) on the intra-
colonic (colo) TNBS-sensitized visceromotor response to graded
colorectal distension was compared in female mice. In animals
treated with 1-week vehicle and then intracolonic TNBS (100μl,
7mg/ml) (•), administered 1 week before the study, signiﬁcant
increased visceromotor response to colorectal distension (∗P<
0.05) was observed, compared to 1-week vehicle and intracolonic
vehicle ( ). One-week CLT treatment did not attenuate the
enhanced visceromotor response to colorectal distension caused by
intracolonic TNBS (). n = 6-7 per group. ∗P<0.01 compared to
1-week vehicle + intracolonic vehicle group.
Table 3: Colonic myeloperoxidase (MPO) issue levels after oral 4%
DSS; eﬀect of therapeutic ceftriaxone.
Treatment (n) Mean ± SEM (units/mg)
1wkveh+oralH 2O[ 4]0 .21 ±0.01
1wkCTX+oralH 2O[ 11]0 .17 ±0.03
1wkveh+4%DSS[4]0 .50 ±0.06a
1wkCTX+4%DSS[4]0 .35 ±0.05a
Ceftriaxone (200mg/kg daily for 1 week), administered one week after
initiationofcolonicinﬂammationbyoral4%DSSinthedrinkingwater,was
ineﬀective to signiﬁcantly reduce colonic inﬂammation, measured by MPO
activity at day 14. aP<0.005 compared to 1-week veh + oral H2O.
animals (Figure 6). However, 1-week CTX treatment after
theestablishmentofcolitis[20]by4%DSSstillproducedsig-
niﬁcantly greater colonic MPO activity compared to 1-week-
vehicle-treated controls (Table 3). These data implicate GLT-
1 overexpression by 1-week CTX treatment as a mediator of
attenuation of DSS-evoked hyperalgesia.
3.6. GLT-1 Overexpression: Eﬀects on Motor Function. An
important question related to possible clinical utility of CTX
treatment is to evaluate possible untoward eﬀects caused by
GLT-1 overexpression. Previous reports show a lack of eﬀect
on acute nociceptive and selective behavioral tests in rodents
[5, 7]. To assess possible eﬀects on general locomotion,Pain Research and Treatment 7
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Figure 6: The eﬀect of GLT-1 overexpression on the dextran-
sodium-sulfate- (DSS-) sensitized visceromotor response to graded
colorectal distension was compared in female mice. In animals
treated with oral 4% DSS for 1 week followed by 1-week daily
vehicle injections (ip) (•), signiﬁcant increased (36–60%) viscero-
motor response to colorectal distension (∗P<0.05) was observed,
compared to 1-week vehicle and intracolonic vehicle ( ). One-
weekCTXtreatmentabolishestheenhanced visceromotorresponse
to colorectal distension caused by oral 4% DSS for 1 week ().
n = 7–9 per group. ∗P<0.01 compared to 1-week vehicle +
intracolonic vehicle group.
the rotarod test was employed to evaluate whether GLT-1
upregulation by one-week CTX treatment alters movement
coordination and balance. Animals were trained on the
rotarod apparatus daily for 1 week; during this time one-
half of the animals were injected with vehicle and the other
half were administered CTX (200mg/kg) daily. There was
no signiﬁcant diﬀerence in the falling latency between CTX
andvehicle-treatedanimals(latencytofall(seconds):vehicle,
251 ± 11; CTX, 292 ± 5). These data suggested that GLT-
1 upregulation by 1-week CTX treatment did not alter the
motor behavioral function in mice.
3.7. Ceftriaxone and Cephalothin: Comparison of Eﬀects on
Intestinal Flora. Emerging evidence suggests that changes
in intestinal microﬂora can mediate alterations in gastroin-
testinal function, including visceral hypersensitivity [21].
To assess a putative role of changes in intestinal ﬂora to
mediate antinociception caused by ceftriaxone (CTX) or
cephalothin (CLT), fecal biota were quantitated after 1-week
administration of either agent, and compared to controls.
Figure 7 shows that both 1-week CTX and CLT cohorts
exhibited a signiﬁcant reduction (39% and 15%, resp.) in
anaerobic lactobacillus, compared to the control group. In
addition, the 1-week CTX but not 1-weak CLT cohort exhib-
ited a signiﬁcant reduction (17%) in aerobic lactobacilli,
compared to control group. Since reductions in lactobacilli
are associated with enhanced visceral hypersensitivity [21]
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Figure 7: Comparison of the eﬀect of 1-week vehicle, CTX or CLT
on mouse fecal pellet biota. The data are the means + SEM of levels
ofﬂoratypesindicatedonthex-axis.n = 8–10pertreatmentgroup.
∗P<0.05 compared to vehicle-treated cohorts.
the CTX-induced reduction in intestinal lactobacilli appears
not to explain its antinociceptive eﬀects. The numbers of (1)
total anaerobes, (2) Gram-positive/Gram-negative aerobes
andfacultativeanaerobes,and(3)gramnegativeaerobesand
facultative anaerobes were not diﬀerent in groups treated
with 1-week CTX or CLT compared to controls.
3.8. AAV9-Mediated GLT-1 Transfection Attenuated the Vis-
ceromotor Response to Colonic Distension. The present study
assessedtheabilityoftransfectionofAAV9-GLT-1constructs
to assess if attenuation of visceral nociception occurs.
Neonatalmicewereinjected with4×10
−11dps ofAAV9-GLT
or vehicle at 19–26d, and the visceromotor response (VMR)
to 60mmHg colorectal distension (CRD) was measured in
these animals at 8 weeks of age. The data show a 62%
reduction in the nociceptive response to 60mmHg pressure
after transfection with AAV9-GLT-1 (n = 10) compared to
animals injected with PBS (n = 10) (Figure 8; P<0.05).
This is correlated with a 111% enhanced glutamate uptake
seen in AAV9-GLT-injected animals compared to controls
(Figure 9).
4. Discussion
The principal ﬁndings of this study were (1) a spinal site of
actionofGLT-1overexpressiontoattenuatevisceralnocicep-
tion, (2) eﬀectiveness of GLT-1 overexpression to attenuate
inﬂammogen-enhanced visceral nociception via both a pre-
emptiveandtherapeuticapproach,(3)CTX-mediatedGLT-18 Pain Research and Treatment
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Figure 8: The visceromotor response to 60mmHg colorectal
distension in mice treated at day 21 with intravenous PBS or AAV9-
GLT-1. The data show a 62% reduction in the nociceptive response
after transfection with GLT-1. n = 10, each group; ∗P<0.05
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Figure 9: Glutamate uptake activity comparison from synapto-
somes of lumbosacral spinal cord of mice administered PBS (n =
6) or AAV9-GLT-1 (n = 6) at 19d by procedures described in
Section 2. The data show a 111% increase in glutamate uptake in
AAV9-GLT-1-treated animals compared to the control group. ∗P<
0.05.
overexpression but not its anti-inﬂammatory eﬀects medi-
ates its antinociceptive eﬀects, (4) translationally superior
adenoassociated virus 9-mediated GLT-1 transfection atten-
uates visceral nociception to 60mmHg colorectal distension,
and (5) alterations in locomotor function were not produced
by 1-week CTX treatment.
Clear evidence by our laboratory and others demon-
strates the eﬀectiveness of 1-week CTX to enhance spinal
GLT-1 expression and glutamate uptake activity [4, 6, 12].
Intrathecal delivery of the selective GLT-1 antagonist DHK
reversed the CTX-blunted visceromotor response to colonic
distension (Figure 1). This result supports the hypothesis
that upregulation of GLT-1 is responsible for the attenu-
ated visceromotor response to colorectal distension. These
ﬁndings are supported by previous work which shows that
(1) intrathecal delivery of CTX produced antinociceptive
eﬀect in both thermal and mechanical nociception tests in
a neuropathic pain model [4], (2) gene transfer of GLT-
1 into spinal cord astrocytes by recombinant adenoviruses
attenuated inﬂammatory and neuropathic pain, probably via
prevention of central sensitization [5], and (3) intrathecal
injection of GLT-1 antisense oligodeoxynucleotides reversed
the antinociceptive eﬀects of 1-week CTX treatment in a
neuropathic pain model [4].
Intracisternal injection of doses of DHK eﬀective after
intrathecal administration (3.0 and 0.3mM) was ineﬀective
to reverse the reduced visceromotor response to colorectal
distensionproducedby1-weekCTXtreatment.Thissuggests
that antagonizing brainstem glutamate transporters does
not alter CTX-blunted visceral nociception. Although the
volume of the fourth ventricle is larger than the intrathecal
space, the concentrations of DHK given intracisternally was
1-2 orders of magnitude greater than the IC 50 of DHK
(0.045mM). These experiments support the exclusion of a
role of brainstem glutamate transporters in mediating the
antinociceptive eﬀects of CTX. However, a role of midbrain,
forebrain, or cerebral glutamate transporters in mediating
antinociceptive eﬀects of 1-week systemic CTX cannot be
ruled out.
These experiments show that GLT-1 upregulation by
one-week CTX treatment eﬀectively reduced visceral hyper-
sensitivity in two animal models of colitis. The myeloperox-
idase (MPO) assay is a well-accepted tool to measure tissue
inﬂammatory damage in animal models of colitis. MPO is a
peroxidase enzyme abundant in neutrophils and is released
upon neutrophil activation by inﬂammatory pathogens [19].
During inﬂammation, the synthesis and release of MPO
are greatly enhanced. MPO has a unique ability to catalyze
chloride and H2O2 to form hypochlorous acid, a powerful
antimicrobial reagent. This unique property is widely used
to detect the amount of MPO in tissue samples by measuring
absorbance at 460nm.
To study potential eﬀectiveness of the intervention of
GLT-1 upregulation during an active inﬂammatory process,
theuseofDSSwasemployedduetothepublishedunreliabil-
ity of TNBS to produce consistent long-term inﬂammation
in murine models [24]. In both the TNBS- and DSS-
induced colitis models, GLT-1 upregulation by one-week
CTX treatment was suﬃcient to mitigate the visceromotor
response to colorectal distention (Figures 3 and 6). TNBS
is a hapten that evokes an acquired immune response [24],
whereas DSS-induced colitis depends on innate immunity
[20]. With regards to the role of the anti-inﬂammatory eﬀect
of CTX itself to mitigate visceral nociception, two lines of
evidence suggest a lack on an important role: (1) in the DSS
model, GLT-1 overexpression had signiﬁcant antinociceptive
eﬀectswithout signiﬁcantly attenuating inﬂammatory eﬀects
of DSS (Figure 6 and Table 3) and (2) 1-week cephalothin,
administered in equimolar doses as CTX,c produced sig-
niﬁcant anti-inﬂammatory eﬀects in TNBS-treated animals
(Table 2), but no reduction in the visceromotor response to
colorectal distension (Figure 5).
Probiotics are emerging as potential treatments of
visceral hypersensitivity [25]. Recent studies suggest that
increase in lactobacilli or its therapeutic administration
produces antinociceptive eﬀects [21]. The fact that CTX
reduces lactobacilli while also producing antinociception
suggests a lack of association between the two events.
Potential clinical utility of the approach to augment glu-
tamate transporter activity depends on the lack of potentialPain Research and Treatment 9
untoward eﬀects. The rotarod test demonstrated that GLT-
1 upregulation by one-week CTX treatment did not alter
motor function, which is consistent with previous studies
showing that CTX treatment did not change performance in
the plus-maze test and open-ﬁeld test, in normal mice [7].
The adenoassociated viral vector (sc AAV9) utilized in
our proposal produces long-term gene expression, thus is
eﬀectiveafterone-timeinjection[23].Thisfactorisalsonon-
immunogenic, and it has shown promise in large animal
species, including monkeys, and as recently reported [11]n o
toxicity was noted in treated animals. The work by Maeda
et al. [5] provided assurance that gene transfer of GLT-1
will work in relieving pain, but the adenovirus used in that
paper activates the immune system and produces only short-
term gene transfer, thus requiring multiple injections, and
thus has limited clinically relevance. Indeed, in some clinical
trials, these agents have produced mortality [23]. The work
performed here regarding GLT-1 transfection represents an
advance in the use of a signiﬁcantly superior viral vector
technology, adenoassociated viral vector (sc AAV9). Selective
targeting of transfection to spinal sites of action would
improve translational prospectus of this approach.
Thus, the data taken together suggests that the antinoci-
ceptive eﬀect of one-week CTX treatment is independent
of its anti-inﬂammatory or probiotic eﬀects and indicates
the importance of GLT-1 upregulation in reducing viscer-
al nociception. Beneﬁcial eﬀects are likely related to reduced
extracellular glutamate tone; thus, less activation of gluta-
mate receptors mediating nociception, and/or second mes-
senger events downstream are attenuated (MAP kinase
activity, AMPA receptor traﬃcking, etc.) [22, 26, 27].
These results support consideration of novel approach
of glutamate transporter upregulation in pain therapeutics.
Further investigation of ceftriaxone and analogues with
increased and more speciﬁc therapeutic eﬀects seem war-
ranted.
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